Over a century ago in Melbourne, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotech company, that same promise has never been stronger. We develop and deliver innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives. We are driven by our deep passion to serve hundreds of thousands of patients and other stakeholders around the world.
Melbourne will see a new high-tech vaccine manufacturing plant in a billion-dollar deal to secure the nation’s long-term supply of critical health products including influenza vaccines and life-saving anti-venoms.
Read More
Blood plasma giant CSL has raised the lower end of its profit guidance for the 2021 June 30, predicting growth of between 3% and 8% in the range of $2.17 to $2.65 billion - a tightening from its August results where the lower end of growth was for no growth.
Read More
CSL shares rose yesterday after its coronavirus vaccine plans formed up. CSL confirmed the sealing of a deal with the federal government to produce the University of Queensland’s COVID-19 vaccine.
Read More
CSL is highly likely to be looking for other avenues of revenue to meet targets in FY21, given a prospective shortfall in plasma collections.
Read More
Thumbs up from investors for CSL’s latest full-year results and confident outlook for the 2020-21 financial year. Australia’s global pharma giant said yesterday it is looking for an 8% rise in earnings for 2020-21 after reporting record sales and a record dividend for 2019-20, despite all the uncertainties caused by the COVID-19 pandemic.
Read More
Foot traffic at around 100 of the company's US-based collection centres has eased in recent weeks. New coronavirus cases in the US have increased and the current seven-day rolling average is ahead of the previous peak.
Read More
UBS observes 139m flu vaccine doses have been distributed for the US flu season till October 9, up 9% versus last year. CSL also reported having increased its supply of flu vaccine into the US to circa 60m doses for the 20-21 season, a 20% increase from last year.
Read More
While CSL is still some way with respect to plasma collection volumes seen last year, UBS believes there are a range of mitigation measures and positive drivers to underpin growth in FY21.
Read More
Macquarie notes foot traffic for around 100 of the US-based collection centres has eased in recent weeks and an increase in new coronavirus cases has been noted over the same period. Current foot traffic sits around -17% below average.
Read More
Credit Suisse believes the pandemic will promote a sustained increase in flu vaccination rates over the next 2-3 years.
Read More
